Burning Rock OncoCompass Target CDx kit enters NMPA priority approval review
BNR•Burning Rock’s OncoCompass Target CDx Kit entered China’s NMPA priority approval procedure for medical devices on Oct. 10, 2026. The kit uses plasma ctDNA for comprehensive genomic profiling.
1. Priority review
Burning Rock’s OncoCompass Target CDx Kit entered China’s NMPA priority approval procedure for medical devices on Oct. 10, 2026. The product is an NGS-based liquid biopsy kit for comprehensive genomic profiling using plasma ctDNA.
